Eosinophilia future or investigational therapies

Eosinophilia Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Eosinophilia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X-Ray
CT
MRI
Other imaging findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Eosinophilia future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Eosinophilia future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Eosinophilia future or investigational therapies
CDC on Eosinophilia future or investigational therapies
Eosinophilia future or investigational therapies in the news
Blogs on Eosinophilia future or investigational therapies
Directions to Hospitals Treating Eosinophilia
Risk calculators and risk factors for Eosinophilia future or investigational therapies

• Eosinophilia is a laboratory finding and is not specifically a target of treatment in most cases
• If the severely elevated eosinophilia count is felt to be the cause of the patient's symptoms, there are a number of treatments that specifically lower eosinophil counts
• Anti-IL5 antibody Mepolizumab is under investigation for use in hypereosinophil syndrome. Mepolizumab has shown potential to rapidly reduce eosinophil counts in trials and reduce the need for corticosteroids.